🐋 SLS Bearish Risk-Reversal — $2.6M Binary Bet Ahead of Pivotal AML Trial Readout

📅 May 20, 2026 | 🔥 Unusual Activity Detected

---

🎯 The Quick Take

Someone just put $2.6M on the table in a sophisticated two-leg risk-reversal on SELLAS Life Sciences — selling $1.4M worth of upside calls while simultaneously buying $1.2M of downside put protection, all at the exact same timestamp. This is not a directional gamble on a tech stock. This is a sophisticated participant positioning around a pivotal Phase 3 clinical trial readout that is literally days to weeks away, pricing real tail risk that the stock drops 60-80% if SELLAS's lead drug fails its once-in-a-decade OS test. Translation: smart money is capping upside and buying downside insurance on a binary clinical event.

---

📊 Company Overview

SELLAS Life Sciences Group (NASDAQ: SLS) is a small-cap clinical-stage immuno-oncology company with a single mission: demonstrate that galinpepimut-S (GPS), a cancer immunotherapy targeting the WT1 protein, can extend the lives of patients with acute myeloid leukemia (AML) who have achieved a second complete remission (CR2) but are not eligible for a bone marrow transplant.

• Market Cap: ≈$1.36B (≈184.5M shares outstanding per the DEF 14A proxy)
• Industry: Clinical-Stage Immuno-Oncology / Biopharmaceuticals
• Current Price: $8.52 (intraday May 20, 2026; up ≈90% YTD and ≈+45% in just the past five sessions per StocksToTrade)
• 52-Week Range: $1.36 – $8.62 (expanded sharply after the May 14 surge per Benzinga)
• Lead Asset: GPS (galinpepimut-S) in AML CR2 maintenance — the REGAL Phase 3 trial
• Secondary Asset: SLS009 (tambiciclib, CDK9 inhibitor) — Phase 2 in relapsed/refractory AML and a newly started first-line AML trial
• Cash: $107.1M as of March 31, 2026, plus a fully untapped $150M ATM facility per the Q1 2026 release
• Institutional investor: BlackRock holds 5%+ per the Schedule 13G/A filing

This is a textbook binary clinical-stage biotech: zero approved products, one pivotal trial that defines the company's near-term fate, and enough cash to stay solvent through the readout. AML is a brutal blood cancer — fewer than 30% of patients over age 60 survive long-term — and there is currently no approved targeted maintenance therapy in the CR2 setting. GPS aims to fill that white space by training the immune system to attack residual cancer cells expressing the WT1 antigen.

---

💰 The Option Flow Breakdown

The Tape — May 20, 2026 @ 10:12:55 (both legs same timestamp, same size):

Net position: ≈$0.2M net debit (nearly cash-neutral). Gross notional: $2.6M committed across both legs.

🤓 What This Actually Means

Two legs. Same second. Same size. Structured as a bearish risk-reversal:

• 🟠 Leg 1 — Sell the $15 Jan-2027 Call (STO): Collect $3.50/share × 400,000 shares = $1.4M cash received. This caps any profit above $15 (76% above current spot). The Vol/OI of 4.76x confirms this is a fresh short — 10,000 contracts traded vs only 2,100 prior open interest — not someone closing an old position.

• 🔵 Leg 2 — Buy the $6 Oct-2026 Put (BTO): Pay $2.90/share × 400,000 shares = $1.2M cash paid. This buys pure downside protection below $6 (a 30% drop from current spot). The Vol/OI of 222x is extraordinary — 10,000 contracts vs only 45 prior OI — this put barely existed before today. Nearly all of this open interest was just created.

The structure in plain English: The trader collects call premium to largely fund a downside insurance policy. If SLS rockets above $15 on a successful REGAL readout, the caller caps out at $15 (they give back any upside above that). If SLS collapses on a failed REGAL readout, the put pays out below $6. Between $6 and $15, both legs expire worthless and the net debit (≈$0.2M) is the total cost.

This is not a pure directional bet. It's a sophisticated binary-event hedge: use expensive call premium (IV elevated on trial anticipation) to cheapen the cost of owning put protection on the tail scenario where the drug fails.

Why this trade structure makes sense ahead of a Phase 3 readout:

A blunt put purchase on SLS right now would be expensive — implied vol is elevated because the market knows the readout is imminent. Selling the call against it is a classic way to reduce that cost while accepting a cap on upside. The trader is effectively saying: "I don't need unlimited upside if GPS works. I'll take $15 as my exit. But I want protection if it fails." That's a rational risk management posture, not a pure bear bet.

---

📈 Technical Setup / Chart Check-Up

YTD Performance Chart

SLS has had a stunning 2026 — the stock started the year near $4.50, bottomed around $1.36 in the 52-week low, and has exploded to $8.52 today, roughly +90% YTD per StockAnalysis. The recent acceleration is almost entirely driven by REGAL event-count updates:

• 📅 December 26, 2025: 72 of 80 OS events reached per Cancer Network
• 📅 May 11-12, 2026: 78 of 80 events reached; SLS closed at $5.22 on May 12 and then ramped ≈45% to $7.59 by May 19 per the TS2 recap
• 📅 May 19, 2026: CEO Angelos Stergiou at the Stifel Targeted Oncology Forum said GPS has "a very good chance" to replicate or improve the earlier ≈13.5-month median OS from the interim, noting some patients remain on therapy three full years after enrollment per Stocktwits / Stifel

Key observations:

• 🚀 Momentum is entirely event-driven: Every meaningful price step higher corresponds to a REGAL event-count disclosure. This is a data stock now — price follows trial news, not technicals.
• ⚠️ Volume and volatility both exploding: The stock has moved 45% in five trading sessions. That's biotech binary behavior — it rewards fast movers and punishes slow ones.
• 🎢 No meaningful technical support structure: After a rally this fast, gamma levels and chart patterns matter less than clinical data. The chart is useful for sizing entry — not for predicting direction.
• 📊 52-week range $1.36 to $8.62: The spread says everything about the binary nature of this name.

Gamma-Based Support and Resistance Analysis

With SLS at $8.52-$8.66, the gamma exposure map shows a relatively thin options market — this is a small-cap biotech, not a mega-cap with billions in open interest. That said, there are meaningful gamma concentrations worth knowing.

🔵 Support Levels (Put Gamma / Blue Bars Below Price):

• $8.00 — Notable call gamma (0.848) and light put gamma (0.029); market makers have hedging interest near round numbers here. Functions as near-term intraday support.
• $7.00 — Meaningful total gamma (1.207, net call-leaning 0.657). This zone has accumulated interest from earlier trading sessions and represents a potential stabilization level on a moderate pullback.
• $6.00 — Total gamma 1.020, more balanced between calls and puts. This is precisely where our BTO put is struck — and it aligns with a real gamma concentration. If SLS breaks $7, market maker dynamics at $6 become the next floor.
• $5.00 — Largest concentration in the lower range at total gamma 1.966, net call-positive 1.471. Significant dealer interest here — this is the major structural support in a severe downside scenario.

🟠 Resistance Levels (Call Gamma / Orange Bars Above Price):

• $9.00 — Moderate call gamma (0.292). Immediate near-term resistance.
• $10.00 — The strongest single resistance level with total gamma 1.974 and net call bias 1.888. This is the dominant call gamma wall — market makers will hedge by selling stock as SLS approaches $10, creating natural resistance. Notably, this also corresponds roughly to the analyst consensus price target of $10-$10.20 per MarketBeat.
• $15.00 — Light gamma (0.207) but this is the STO call strike. Above $15, our risk-reversal trader is capped out. The Jan-2027 call the whale sold is right at this level.

Net GEX Bias: Broadly call-positive (bullish dealer positioning) but thin. The call gamma concentration at $10 is the dominant near-term ceiling. The $5 gamma floor is the key support in a trial-miss scenario.

What this means for traders: The gamma map is telling us $10 is the wall and $5-$7 is the landing zone if things go wrong. The risk-reversal structure essentially brackets this map: the $6 put protects against a break through the $5-$7 support zone, and the $15 call cap sits well above any gamma resistance that matters near-term.

Implied Move Analysis

The options market is pricing in extreme volatility around this clinical binary. Here's what the IV term structure is telling us:

• 📅 Weekly (May 22 — 2 days): ±$0.87 (±10.1%) → Range: $7.79 – $9.53
• 📅 Monthly OPEX (June 19 — 30 days, REGAL readout window): ±$5.65 (±65.2%) → Range: $3.01 – $14.31
• 📅 July 17 OPEX (puts expiry month approaches): Upper $15.78 / Lower $1.54
• 📅 Oct 16, 2026 — put expiry date: Upper $19.60 / Lower −$2.28 (floor implied at ≈$0 for small-cap)
• 📅 Jan 15, 2027 — call expiry date: Upper $23.43 / Lower −$6.11 (again floor at ≈$0)

Translation for regular folks: The market is pricing a 10% move in just two days (weekly) — and for the June OPEX window (which captures the REGAL readout), it's pricing a 65% move either direction. That is not a typo. That implied move of ±$5.65 with SLS at $8.66 means the market thinks there's a real probability of SLS trading anywhere from $3 to $14 by June 19.

By the put's October 16 expiry, the lower end of the implied range essentially goes to zero — the options market is telling you plainly: if REGAL fails, this stock goes to near-zero. That is the tail risk the $6 put is purchasing protection against.

The upper end of $19.60 by October suggests that a successful REGAL readout could drive SLS into the high teens or low twenties — which is why the whale sold the $15 call. They're betting: "If it works, I'll take $15. I don't need $20."

Key insight: A 65% implied move for a 30-day window is EXTREME even for small-cap biotech. Comparable Phase 3 binary readouts in the AML / hematology space (like Rigel's fostamatinib or Blueprint's pralsetinib) have produced single-session moves of 40-80% in either direction. This is the market pricing that kind of event correctly.

---

🎪 Catalysts

🔥 Dominant Binary Catalyst — REGAL Phase 3 Final OS Readout (IMMINENT)

This is the only catalyst that matters right now. Everything else is noise by comparison.

What REGAL is: The Randomized, Evaluation of Galinpepimut-S in AML (REGAL) trial is a Phase 3 study of GPS versus best available therapy in adult AML patients in second complete remission (CR2) who are not eligible for allogeneic stem cell transplant. Primary endpoint: overall survival (OS). Per Targeted Oncology's REGAL overview, the trial requires 80 OS events to trigger the final analysis. The success criterion is ≈12.6 months median OS on GPS versus ≈8.1 months on control.

Where we are right now: As of May 11, 2026, 78 of 80 required OS events have occurred per the SELLAS Q1 2026 release via StockTitan. The 80th event triggers:

1. Database lock
2. Blinded statistical review
3. Unblinding
4. Topline disclosure (typically within days to a week of the 80th event)

The CEO said at the Stifel Forum on May 19 that the data could arrive "within weeks" of the 80th event — and interpreting the pace from 72 events (December 2025) to 78 events (May 11, 2026) suggests the final two events could arrive any day now. This is a June–July 2026 readout with high probability, landing well inside the October 16 put expiry window.

Why the slow pace to the 80th event is actually a bullish signal: The last 6 events took ≈5 months (December 2025 to May 2026). That means patients in the trial are surviving longer than the historical control arm benchmark of ≈6-8 months in CR2 AML. CEO Stergiou specifically flagged this — some patients are still on GPS therapy three years after enrollment per Stocktwits / Stifel recap. That's consistent with a drug that's working.

Third-party probability estimate: Vola Corvidae's Monte-Carlo simulation model estimates a ≈77% probability of REGAL success — substantially above the typical Phase 3 oncology base rate of ≈40-50%. The model reflects the favorable interim (no futility stops, no safety halts), the decreasing death rate as enrollment matures, and the orphan/CR2 setting. This is a third-party model, not a company estimate, but it is a meaningful data point.

What success looks like: A clean OS hit (p ≤ 0.05, HR well below 0.80) triggers: potential BLA filing in H2 2026; possible Priority Review Voucher worth $100M+ on the open market via the Rare Pediatric Disease Designation; potential milestone payments from the 3D Medicines China license (up to $202M). The FDA has already provided favorable Type C CMC feedback on the BLA manufacturing strategy — the regulatory prep work is done.

What failure looks like: A single-trial miss at this sample size (126 patients in CR2 AML) has no fallback. SLS has no approved product. The drug goes back to earlier-stage development or is abandoned. The stock would likely revisit the $2-$3 pre-rally range per stockanalysis.com historical pricing — a 65-80% drawdown from current levels.

📅 Near-Term Conference Catalysts (Next 2 Weeks)

• A.G.P. Annual Virtual Healthcare Conference — May 20, 2026 at 11:00 AM ET. CEO Stergiou fireside chat per SELLAS press release. Happening today — the same day as this trade.
• TD Cowen 7th Annual Oncology Innovation Summit — May 27, 2026 at 9:00 AM ET per SELLAS press release.
• ASCO 2026 Annual Meeting (Chicago) — May 29 – June 2, 2026 per ASCO annual meeting page. No confirmed SELLAS abstract as of May 20, but ASCO is a plausible backdrop for a REGAL topline press release if the 80th event lands in late May. As a reference, SELLAS presented SLS009 preclinical work at ASCO 2025 per this GlobeNewswire release.

📊 Secondary Catalyst — SLS009 in AML (Q4 2026)

SLS009 (tambiciclib) — a CDK9 inhibitor — enrolled its first patient in a newly diagnosed first-line AML Phase 2 trial on March 12, 2026. Topline data is expected in Q4 2026. At ASH 2025, SLS009 showed a 46% overall response rate in relapsed/refractory VEN-resistant AML-MR (the hardest-to-treat population) per the StockTitan ASH recap — best-in-class for that population. The SLS009 topline falls outside the Oct-16 put expiry but inside the Jan-2027 call window, adding a secondary catalyst dimension for the short-call leg.

⚠️ Overhang — ATM Dilution Risk

Management has a $150M ATM facility with TD Cowen that has seen zero draws to date per the Q1 2026 release. A successful REGAL readout typically creates an opportunity for management to raise equity at strength. That dilution risk — selling shares into a rally — partly explains why a sophisticated participant might sell the call: they're not convinced the stock stays above $15 even in the success case after ATM dilution.

---

🎲 Price Targets and Probabilities

Using gamma levels, implied move data, and clinical context:

📈 Bull Case — ≈55% Probability (base probability adjusted from Vola Corvidae 77% PoS, discounted for post-success dilution and "borderline hit" scenarios)

Target: $10–$15 (and capped there by the short call)

How we get there:

• ✅ REGAL hits OS primary endpoint with a clean p-value and a hazard ratio below 0.75 (strong separation)
• 🚀 Press release drops June–July 2026; stock gaps 40-80% on open based on historical Phase 3 hematology precedents
• 📊 BLA filing announcement within weeks; potential partnership / licensing discussions emerge
• 💊 CEO commentary at post-data conference highlights broad unmet need (WT1-positive AML covers a large patient population)
• 🏦 Analyst consensus target range of $10–$10.20 per MarketBeat gets revised upward toward $15-$20 on BLA filing
• 📈 $10 gamma wall gets absorbed; stock pushes toward $12-$15 as BLA prep and partnership speculation drives premium

Risk-reversal P&L in bull case:

• At $12 on Oct 16: short call at $15 is deep OTM and nearly worthless (good for the short call leg), long put at $6 is deep OTM and worthless. Net position: collect ≈$0.2M net vs. lose ≈$0.4M on the call intrinsic if held to January — overall loss of ≈$0.2M net debit already paid.
• At $15 on Jan 15, 2027: short call breaks even — maximum upside from spot ($15 – $8.52 = $6.48/share × 400,000 = $2.6M gain on the underlying). The short call caps that to $15 — the caller receives $3.50 in premium and that's all.

🎯 Base Case — ≈22% Probability

Target: $6–$9 (chop around current levels pending data)

Most likely scenario if readout is delayed or "borderline":

• ⚖️ The 80th OS event is delayed into August–September 2026 (further behind schedule), keeping SLS in a holding pattern
• 📊 "Good but not clean" topline: OS hit at p ≈ 0.04-0.05 with wide confidence intervals; stock rallies 20-30% but gives back half as uncertainty about FDA approval lingers
• 🔄 Stock trades between $7 and $10 as investors debate BLA approvability — both options legs expire with minimal value
• 💤 Vol crush post-readout drives both the put and short call toward intrinsic-only pricing

📉 Bear Case — ≈23% Probability (Vola Corvidae "miss" probability, consistent with typical Phase 3 oncology failure rate)

Target: $1.50–$3.50 (catastrophic drawdown)

What failure looks like:

• ❌ REGAL misses the primary OS endpoint: hazard ratio does not reach statistical significance
• 😰 Stock loses 60-80% in a single session; trading halt likely before market open on data day
• 📉 Per stockanalysis.com historical data, SLS was in the $2-$3 range before the REGAL event-count updates drove the rally — that is the likely reset level
• 💸 Cash ($107.1M) provides ≈3+ quarters of runway per StockTitan Q1 recap but no approved product means company enters restructuring mode
• 🔵 Long Put P&L: At $3 on Oct 16, the $6 put is worth $3.00/share × 400,000 shares = $1.2M profit. Against the $1.2M debit paid, the put is a near-breakeven hedge — but it fully offsets the cost of the structure, meaning the caller-structured trade becomes cost-free insurance in hindsight.
• At $2, the put is worth $4 × 400,000 = $1.6M, and the net position earns $0.4M after backing out the $1.2M put cost.

---

💡 Trading Ideas

🛡️ Conservative: Watch, Do Not Trade Until the Readout

Play: Stay entirely on the sidelines until the REGAL topline is announced.

Why this works (or rather: why touching this before the readout is dangerous):

• ⏰ The 80th OS event is imminent. This is a binary clinical catalyst that will resolve itself in days to weeks. There is no technical setup, no earnings call to game, no quarterly guidance to read. Either the trial works or it doesn't.
• 💸 Options are extremely expensive. A 65% implied move for 30-day expiry is not normal. You are paying peak volatility just to have an opinion. If you buy a put and the drug works — you lose 100% of premium the same morning.
• 🎯 Wait for the readout, then act. If GPS hits: look for the initial pop to absorb, then evaluate whether the BLA path, PRV optionality, and SLS009 pipeline justify a position at the post-readout price. If GPS misses: the $5 gamma floor and $107M cash provide a base, but a 60-70% air pocket is not a dip you catch in real time.

Risk level: Minimal (cash) | Skill level: Beginner-friendly — this is the right move for most retail traders on a name this binary.

⚖️ Balanced: Post-Readout Long Call Spread (Success Scenario)

Play: If REGAL hits and stock gaps to $10-$11 on the open, consider a defined-risk long-call spread for the BLA filing and PRV optionality runway.

Structure (post-readout, after IV partially collapses): Buy the $10 call, sell the $15 call — Jan 2027 expiration (same as the STO call in the whale trade).

Why this works:

• 🎯 After a success gap, IV will partially crush — you buy the spread at lower vol than pre-event pricing
• 📊 $10-$15 range spans from the gamma wall to the analyst target ceiling and the short-call strike
• ⏰ Jan 2027 captures BLA filing announcement, potential PRV sale news, and early partnership speculation
• 💰 Estimated cost: $1.50-$2.50 per spread post-readout (max risk = debit paid per spread)
• 📈 Max profit: $3.50-$4.50 if SLS reaches $15 by January 2027

Risk: If readout is delayed or is a "borderline" hit that the market doesn't celebrate, the spread bleeds theta. Max loss is the debit paid. Never risk more than 1-3% of portfolio.

Risk level: Moderate (defined risk) | Skill level: Intermediate

🚀 Aggressive: Mimic the Whale's Risk-Reversal (ADVANCED ONLY)

Play: Replicate a smaller version of the risk-reversal — sell Jan 2027 $15 calls and buy Oct 2026 $6 puts in a defined ratio.

Why this could work:

• 💰 The structure is nearly cash-neutral — call premium funds most of the put purchase
• 🎢 You own downside protection below $6 for a 23% tail-risk scenario (per Vola Corvidae miss probability)
• 🔵 You cap your upside but accept that in a 77% success scenario, you'll still hold the stock from $8.52 to $15 (a potential 76% gain) without the option position adding much

Why this is not for everyone:

• ⚠️ Selling naked calls on a clinical-stage biotech is EXTREMELY dangerous. If GPS hits with spectacular data and SLS gaps to $20 or $25 on day one — you owe the difference above $15. A small-cap can move 100%+ in a single session on pivotal Phase 3 data. The call needs to be covered by owning SLS shares or cash-secured, not written naked.
• 📋 Margin requirements for selling SLS calls will be substantial at most brokers given the binary event risk
• 🎰 You need to be OK with a scenario where SLS goes to $25 and you have unlimited loss above $15

If you do attempt this: Only with shares held (covered call), never naked. Size to 1-2% of total portfolio maximum.

Risk level: EXTREME (unlimited upside loss on the short call if uncovered) | Skill level: Advanced only

---

⚠️ Risk Factors

If you are considering any position in SLS, read every one of these carefully.

• 🎰 This is a binary clinical event, not a technical trade. REGAL will either hit or miss. The stock will either gain 50-100% or lose 60-80% — potentially in a single trading session. Charts, support levels, and moving averages are irrelevant on data day. Your position sizing must reflect that this is not a manageable swing trade; it is a lottery ticket with a specific expiration date.

• ❌ REGAL can fail even with a 77% modeled probability. The Vola Corvidae estimate is a third-party model, not a guarantee. Phase 3 trials with favorable interims and high interim PoS estimates have still failed — Ampio Pharmaceuticals (Ampion in OA), Sorrento Therapeutics (COVID), Genocea's ATLAS-TN all come to mind. A 23% miss probability means roughly 1 in 4 trials at this confidence level still fail. Do not bet more than you can afford to lose entirely.

• 💉 Even a "successful" readout can disappoint. A borderline p-value (0.04-0.05), wide confidence intervals, subgroup heterogeneity, or OS curves that cross late will generate immediate debate about FDA approvability. A "mixed" hit can produce a 10-20% rally that fades, not a 60-80% re-rating. Context of the data matters as much as the headline.

• 💧 ATM dilution is the immediate risk after a positive readout. SELLAS has a $150M ATM facility that has never been used. Post-success, management has every incentive to raise capital at $12-$15 to fund commercial readiness. That selling pressure — issuing new shares into the rally — is part of why a sophisticated whale capped their upside at $15. The call seller is being honest: even if GPS works, $15 may be a reasonable ceiling because of dilution.

• 📉 Small-cap biotech liquidity risk. The $6 put had 45 contracts of open interest before today. 10,000 new contracts were just created. If SLS is headed toward $3 on a trial failure, bid-ask spreads on that put will blow out — you may not be able to exit at the theoretical value. Options in thin names can have 10-20% bid-ask spreads in stress.

• 🏦 Lack of approved products = no commercial floor. Unlike a large-cap pharma with a diversified product portfolio, if REGAL fails, SLS has no revenue, no approved drug, and its only near-term catalyst disappears. Cash provides ≈3 quarters of runway at current burn but not much longer without a financing. The equity is not protected by assets.

• 🔬 FDA BLA approval is not automatic even with a positive trial. The favorable Type C CMC feedback noted above is constructive but relates only to manufacturing, not clinical approvability. With a 126-patient Phase 3 in an orphan setting, the FDA could request additional confirmatory data — particularly if confidence intervals are wide or subgroup analysis shows heterogeneity.

• 🌐 Broader biotech tape risk. XBI was down 0.7% on May 19 while SLS was rallying on CEO commentary. If the broader biotech sector sells off into the summer, even positive REGAL data may be partially absorbed by sector-level selling pressure.

---

🎯 The Bottom Line

Real talk: Someone just structured a ≈$2.6M options position to specifically hedge around SELLAS's REGAL Phase 3 readout — and they did it in a way that is almost cost-neutral. They are not predicting failure. They are saying: "I acknowledge this trial could fail, and if it does, I want protection below $6. I'll pay for that protection by giving up upside above $15."

That is textbook risk management for a binary clinical event, not a prediction.

What this trade tells us:

• 🎯 A sophisticated participant thinks the 60-80% downside tail on a REGAL miss is real enough to hedge — even at 77% modeled success probability, the asymmetry of a miss is severe enough to warrant insurance
• 💰 The $15 call sale at a 4.76x Vol/OI ratio is fresh and deliberate — they're accepting a cap because they believe dilution and the $10 gamma wall limit upside to $15 or below even in the success case
• 📊 The 222x Vol/OI on the put is extreme — this protection was essentially nonexistent in the market before today; someone needed it badly enough to create it from scratch
• ⏰ October 16, 2026 put expiry captures the REGAL readout almost certainly. January 2027 call expiry captures a potential SLS009 Q4 data read and full BLA filing cycle

This is not a "sell everything" signal. It is a "the market is pricing a very wide outcome range and one sophisticated participant has chosen to bracket it."

If you own SLS stock:

• ✅ Consider whether your position sizing reflects a genuine willingness to hold through a 60-80% overnight drop if REGAL misses
• 📊 The $7 gamma level (total gamma 1.207) and $5 gamma floor (total gamma 1.966) are the only meaningful support structures between here and the pre-rally levels
• ⏰ If you plan to hold through the readout, accept that the position may need to be sized at 1-2% of portfolio maximum, not more
• 🛡️ If you want to partially hedge like the whale: the Oct 2026 $6 put at ≈$2.90 costs ≈34% of current spot — expensive but priced for a reason

If you are watching from the sidelines:

• ⏰ The REGAL readout is the only calendar that matters. CEO said "within weeks" at the Stifel Forum on May 19 — based on the pace of events, that likely means June or early July 2026. Mark your calendar and do not trade ahead of that binary.
• 🎯 Post-readout on a hit: the initial gap will be chaotic. Wait for the first 30-60 minutes to settle, then evaluate buying the $10-$15 Jan call spread as the BLA filing cycle begins (see balanced trading idea above).
• ⚠️ Post-readout on a miss: the stock will likely open 50-70% lower and halt. Do not try to catch the falling knife on data day. Cash provides a floor, but the $2-$3 range represents months of restructuring news flow before any recovery.

If you are bearish:

• 🎯 The $6 Oct 2026 put is now active and has real open interest thanks to today's trade — but at ≈$2.90, you are paying 34% of the stock's current price for protection. That is expensive. The risk/reward only makes sense if you size it as a hedge against an existing long, not as a standalone speculative trade.
• 📊 The $5 gamma floor is the key structural support on the downside — below $5, the gamma map shows significantly less cushion.

Mark your calendar — Key dates:

• 📅 May 20, 2026 — A.G.P. Healthcare Conference fireside chat with CEO Stergiou at 11:00 AM ET
• 📅 May 27, 2026 — TD Cowen Oncology Innovation Summit at 9:00 AM ET
• 📅 May 29 – June 2, 2026 — ASCO 2026 Annual Meeting — potential backdrop for REGAL announcement
• 📅 June – July 2026 (estimated) — REGAL Phase 3 final OS topline readout. The defining moment for SLS.
• 📅 Mid-August 2026 — Q2 2026 earnings (likely REGAL update if not yet reported)
• 📅 October 16, 2026 — BTO put expiry date (captures the REGAL readout)
• 📅 Q4 2026 — SLS009 first-line AML topline data per Q1 2026 release
• 📅 January 15, 2027 — STO call expiry date (the whale's upside cap expires)

Final verdict: SELLAS is two OS events away from the trial that defines its existence. The options market is pricing a 65% implied move into the June OPEX and essentially zero lower bound for SLS by October. The whale trade today is not a statement about whether GPS works — it's a statement that when a single 126-patient trial determines whether a $1.36B company becomes a $3B commercial entity or a $200M shell, both outcomes deserve a seat at the table. Smart money is paying for that optionality in both directions.

For most retail traders: wait for the readout. This is not a name to trade on intuition or chart analysis. It is a clinical binary, and the only edge available right now is patience.

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. Clinical-stage biotech stocks can lose 60-80% of their value in a single trading session on trial failure. This analysis is for educational and informational purposes only and does not constitute financial advice. The risk-reversal structure described here involves selling call options (which carry significant risk of loss if uncovered) and buying put options (which can expire worthless). Past performance of similar trades or comparable clinical events does not guarantee future results. The Vola Corvidae PoS estimate of ≈77% is a third-party model and not a company-sponsored figure — Phase 3 trials with high modeled success probabilities fail regularly. Always consult a licensed financial advisor before making options trades, particularly around binary clinical events. Position size appropriately for the possibility of total loss.

---

About SELLAS Life Sciences Group: SELLAS Life Sciences is a clinical-stage immuno-oncology company developing galinpepimut-S (GPS) for AML CR2 maintenance in the pivotal Phase 3 REGAL trial, and SLS009 (tambiciclib) for relapsed/refractory and newly diagnosed AML. Market cap approximately $1.36 billion. No approved products. Binary clinical readout expected within weeks.